Last reviewed · How we verify

stander treatment pregabalin — Competitive Intelligence Brief

stander treatment pregabalin (stander treatment pregabalin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gabapentinoid; anticonvulsant; anxiolytic. Area: Neurology; Pain Management; Psychiatry.

marketed Gabapentinoid; anticonvulsant; anxiolytic Alpha-2-delta subunit of voltage-gated calcium channels Neurology; Pain Management; Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

stander treatment pregabalin (stander treatment pregabalin) — Hawler Medical University. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
stander treatment pregabalin TARGET stander treatment pregabalin Hawler Medical University marketed Gabapentinoid; anticonvulsant; anxiolytic Alpha-2-delta subunit of voltage-gated calcium channels
Gabapentin/B-complex Gabapentin/B-complex Merck KGaA, Darmstadt, Germany marketed Anticonvulsant/analgesic combination with vitamin supplementation Alpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)
Pregabalin capsule Pregabalin capsule Guang'anmen Hospital of China Academy of Chinese Medical Sciences marketed Gabapentinoid; anticonvulsant; anxiolytic Alpha-2-delta subunit of voltage-gated calcium channels
Lyrica (pregabalin) Lyrica (pregabalin) Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Gabapentinoid; anticonvulsant; anxiolytic Alpha-2-delta subunit of voltage-gated calcium channels
Pregabalin Dose Level 1 Pregabalin Dose Level 1 Pfizer's Upjohn has merged with Mylan to form Viatris Inc. phase 3 Gabapentinoid; anticonvulsant; anxiolytic; analgesic Alpha-2-delta subunit of voltage-gated calcium channels
Gabapentin Pill Gabapentin Pill Shanghai Zhongshan Hospital phase 3 Anticonvulsant / Gabapentinoid Alpha-2-delta subunit of voltage-gated calcium channels
Gabapentin Extended Release tablets Gabapentin Extended Release tablets Depomed phase 3 Anticonvulsant / Analgesic Alpha-2-delta subunit of voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gabapentinoid; anticonvulsant; anxiolytic class)

  1. AstraZeneca · 1 drug in this class
  2. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
  3. Hawler Medical University · 1 drug in this class
  4. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). stander treatment pregabalin — Competitive Intelligence Brief. https://druglandscape.com/ci/stander-treatment-pregabalin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: